JP2018021046A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018021046A5 JP2018021046A5 JP2017155657A JP2017155657A JP2018021046A5 JP 2018021046 A5 JP2018021046 A5 JP 2018021046A5 JP 2017155657 A JP2017155657 A JP 2017155657A JP 2017155657 A JP2017155657 A JP 2017155657A JP 2018021046 A5 JP2018021046 A5 JP 2018021046A5
- Authority
- JP
- Japan
- Prior art keywords
- disorder
- pharmaceutical composition
- dosage form
- unit dosage
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 201000010099 disease Diseases 0.000 claims 8
- 150000001875 compounds Chemical class 0.000 claims 6
- 239000002552 dosage form Substances 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- 125000000217 alkyl group Chemical group 0.000 claims 2
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 125000001475 halogen functional group Chemical group 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 239000011780 sodium chloride Substances 0.000 claims 2
- 239000012453 solvate Substances 0.000 claims 2
- -1 1-naphth-2-ylethyl Chemical group 0.000 claims 1
- 206010003210 Arteriosclerosis Diseases 0.000 claims 1
- 208000001284 Hemoglobinopathy Diseases 0.000 claims 1
- 206010052739 Immunodeficiency disorder Diseases 0.000 claims 1
- 208000009856 Lung Disease Diseases 0.000 claims 1
- 208000002780 Macular Degeneration Diseases 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- 208000006551 Parasitic Disease Diseases 0.000 claims 1
- 208000006641 Skin Disease Diseases 0.000 claims 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 1
- 108010001801 Tumor Necrosis Factor-alpha Proteins 0.000 claims 1
- 230000002159 abnormal effect Effects 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 230000033115 angiogenesis Effects 0.000 claims 1
- 239000010425 asbestos Substances 0.000 claims 1
- 201000001320 atherosclerosis Diseases 0.000 claims 1
- 238000009566 cancer vaccine Methods 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 201000009910 diseases by infectious agent Diseases 0.000 claims 1
- 201000003923 hemoglobinopathy Diseases 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 125000001326 naphthylalkyl group Chemical group 0.000 claims 1
- 125000004923 naphthylmethyl group Chemical group C1(=CC=CC2=CC=CC=C12)C* 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 229910052895 riebeckite Inorganic materials 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 201000010874 syndrome Diseases 0.000 claims 1
Claims (12)
- 式
の化合物、またはその医薬的に許容可能な塩、溶媒和物もしくは立体異性体
[式中、
Yは、C=Oであり、
R1は、ナフチルアルキルであり、R1は、アルコキシ、ハロ、アルキルおよびアルキルスルホニルから選択される1つまたは複数の基で置換されていてもよい]。 - R1が、アルコキシ、ハロ、アルキルおよびアルキルスルホニルから選択される1つまたは複数の置換基で置換されている、請求項1に記載の化合物。
- R1が、ナフチルメチルである、請求項1または2に記載の化合物。
- R1が、1−ナフト−2−イルエチルである、請求項1に記載の化合物。
- 請求項1から4のいずれか1項に記載の化合物、またはその医薬的に許容可能な塩、溶媒和物もしくは立体異性体を含有する医薬組成物。
- 癌、血管新生関連障害、疼痛、黄斑変性もしくはその関連症候群、皮膚病、肺障害、アスベスト関連障害、寄生虫病、免疫不全障害、CNS障害、CNS損傷、アテローム性動脈硬化症もしくはその関連障害、機能不全睡眠もしくはその関連障害、感染症、異常ヘモグロビン症もしくはその関連障害、またはTNFα関連障害の治療、維持または予防のための請求項5記載の医薬組成物。
- 1または複数種類の追加の活性成分と併用されることを特徴とする、請求項6に記載の医薬組成物。
- 前記疾患が、癌であり、前記追加の活性薬剤が、癌ワクチンである、請求項7に記載の医薬組成物。
- 請求項1ないし4に記載の化合物を含む単位投与剤形。
- 経口または非経口投与される請求項9記載の単位投与剤形。
- 経口投与に適する、請求項10に記載の単位投与剤形。
- 錠剤またはカプセルである、請求項10に記載の単位投与剤形。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US91932307P | 2007-03-20 | 2007-03-20 | |
US60/919,323 | 2007-03-20 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015211991A Division JP6373818B2 (ja) | 2007-03-20 | 2015-10-28 | 4’−o−置換イソインドリン誘導体および該誘導体を含有する組成物およびその使用方法 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2018021046A JP2018021046A (ja) | 2018-02-08 |
JP2018021046A5 true JP2018021046A5 (ja) | 2018-06-14 |
JP6448726B2 JP6448726B2 (ja) | 2019-01-09 |
Family
ID=39719168
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2009554563A Withdrawn JP2010522170A (ja) | 2007-03-20 | 2008-03-19 | 4’−o−置換イソインドリン誘導体および該誘導体を含有する組成物およびその使用方法 |
JP2014129790A Active JP5927241B2 (ja) | 2007-03-20 | 2014-06-25 | 4’−o−置換イソインドリン誘導体および該誘導体を含有する組成物およびその使用方法 |
JP2015211991A Active JP6373818B2 (ja) | 2007-03-20 | 2015-10-28 | 4’−o−置換イソインドリン誘導体および該誘導体を含有する組成物およびその使用方法 |
JP2017155657A Active JP6448726B2 (ja) | 2007-03-20 | 2017-08-10 | 4’−o−置換イソインドリン誘導体および該誘導体を含有する組成物およびその使用方法 |
Family Applications Before (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2009554563A Withdrawn JP2010522170A (ja) | 2007-03-20 | 2008-03-19 | 4’−o−置換イソインドリン誘導体および該誘導体を含有する組成物およびその使用方法 |
JP2014129790A Active JP5927241B2 (ja) | 2007-03-20 | 2014-06-25 | 4’−o−置換イソインドリン誘導体および該誘導体を含有する組成物およびその使用方法 |
JP2015211991A Active JP6373818B2 (ja) | 2007-03-20 | 2015-10-28 | 4’−o−置換イソインドリン誘導体および該誘導体を含有する組成物およびその使用方法 |
Country Status (25)
Country | Link |
---|---|
US (6) | US8153659B2 (ja) |
EP (2) | EP2142534B1 (ja) |
JP (4) | JP2010522170A (ja) |
KR (3) | KR20090121400A (ja) |
CN (2) | CN103641814A (ja) |
AR (1) | AR065810A1 (ja) |
AU (1) | AU2008229383B2 (ja) |
BR (1) | BRPI0809011A8 (ja) |
CA (1) | CA2681633C (ja) |
CL (1) | CL2008000805A1 (ja) |
CO (1) | CO6231033A2 (ja) |
CR (2) | CR11036A (ja) |
EC (1) | ECSP099663A (ja) |
ES (2) | ES2601131T3 (ja) |
IL (1) | IL200990A (ja) |
MX (1) | MX2009010082A (ja) |
MY (1) | MY180812A (ja) |
NI (1) | NI200900170A (ja) |
NZ (2) | NZ599199A (ja) |
PE (1) | PE20081894A1 (ja) |
RU (1) | RU2471794C2 (ja) |
UA (1) | UA97976C2 (ja) |
UY (1) | UY30977A1 (ja) |
WO (1) | WO2008115516A2 (ja) |
ZA (1) | ZA200906497B (ja) |
Families Citing this family (64)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2929331B2 (ja) * | 1990-07-18 | 1999-08-03 | 丸善石油化学株式会社 | トラクションドライブ用流体 |
ZA200704964B (en) * | 2004-12-01 | 2008-10-29 | Celgene Corp | Methods and compositions using immunomodulatory compounds for the treatment of immunodeficiency disorders |
KR20090121400A (ko) | 2007-03-20 | 2009-11-25 | 셀진 코포레이션 | 4'-o-치환된 아이소인돌린 유도체 및 이를 포함하는 조성물 및 이의 사용 방법 |
WO2009085234A2 (en) * | 2007-12-20 | 2009-07-09 | Signal Pharmaceuticals, Inc. | Use of micro-rna as a biomarker of immunomodulatory drug activity |
CA2781888C (en) * | 2009-12-11 | 2019-06-18 | Nono Inc. | Agents and methods for treating ischemic and other diseases |
SI3202461T1 (sl) * | 2010-02-11 | 2019-05-31 | Celgene Corporation | Derivati arilmetoksi izoindolina in sestavki, ki jih vsebujejo in metode uporabe le teh |
AU2013245487B2 (en) * | 2010-02-11 | 2016-03-10 | Celgene Corporation | Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same |
AU2016203826B2 (en) * | 2010-02-11 | 2018-05-17 | Celgene Corporation | Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same |
WO2012135299A1 (en) | 2011-03-28 | 2012-10-04 | Deuteria Pharmaceuticals Inc | 2',6'-dioxo-3'-deutero-piperdin-3-yl-isoindoline compounds |
WO2012174488A2 (en) * | 2011-06-15 | 2012-12-20 | Nono, Inc. | Agents and methods for treating ischemic and other diseases |
CN102731853B (zh) * | 2012-06-28 | 2013-11-27 | 芜湖宏达橡塑阀门制造有限公司 | 耐油橡胶 |
CN102731851B (zh) * | 2012-06-28 | 2013-11-27 | 芜湖宏达橡塑阀门制造有限公司 | 一种耐油橡胶 |
CN102731850B (zh) * | 2012-06-28 | 2013-11-27 | 芜湖宏达橡塑阀门制造有限公司 | 耐油耐磨橡胶 |
US9133161B2 (en) * | 2012-07-27 | 2015-09-15 | Celgene Corporation | Processes for preparing isoindoline-1,3-dione compounds |
CA2879151C (en) | 2012-08-09 | 2021-03-30 | Celgene Corporation | Processes for the preparation of (s)-3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and pharmaceutically acceptable forms thereof |
SG11201500983RA (en) | 2012-08-09 | 2015-04-29 | Celgene Corp | Treatment of immune-related and inflammatory diseases |
JP6347782B2 (ja) * | 2012-08-09 | 2018-06-27 | セルジーン コーポレイション | 3−(4−((4−(モルホリノメチル)ベンジル)オキシ)−1−オキソイソインドリン−2−イル)ピペリジン−2,6−ジオンを使用する癌の治療方法 |
US20150038511A1 (en) | 2012-08-09 | 2015-02-05 | Celgene Corporation | Treatment of immune-related and inflammatory diseases |
EP2943201B2 (en) | 2013-01-14 | 2020-07-29 | Deuterx, LLC | 3-(5-substituted-4-oxoquinazolin-3(4h)-yl)-3-deutero-piperidine-2,6-dione derivatives |
WO2014116573A1 (en) | 2013-01-22 | 2014-07-31 | Celgene Corporation | Processes for the preparation of isotopologues of 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and pharmaceutically acceptable salts thereof |
US9242966B2 (en) | 2013-03-11 | 2016-01-26 | Bristol-Myers Squibb Company | Phthalazines as potassium ion channel inhibitors |
WO2014152833A1 (en) | 2013-03-14 | 2014-09-25 | Deuterx, Llc | 3-(substituted-4-oxo-quinazolin-3(4h)-yl)-3-deutero-piperidine-2,6-dione derivatives |
US20140314752A1 (en) | 2013-04-17 | 2014-10-23 | Signal Pharmaceuticals, Llc | Methods for treating cancer using tor kinase inhibitor combination therapy |
UA117141C2 (uk) | 2013-10-08 | 2018-06-25 | Селджин Корпорейшн | Склади (s)-3-(4-((4-(морфолінометил)бензил)оксі)-1-оксоізоіндолін-2-іл)піперидин-2,6-діону |
WO2015179276A1 (en) | 2014-05-19 | 2015-11-26 | Celgene Corporation | 3-(4-((4-(morpholinomethyl-benzyl)oxy)-1 -oxoisoindolin-2-yl)piperidine-2,6-dione for the treatment of systemic lupus erythematosus |
KR102191256B1 (ko) * | 2014-10-30 | 2020-12-15 | 강푸 바이오파마슈티칼즈 리미티드 | 이소인돌린 유도체, 이의 중간체, 제조방법, 약물 조성물 및 응용 |
US9809603B1 (en) | 2015-08-18 | 2017-11-07 | Deuterx, Llc | Deuterium-enriched isoindolinonyl-piperidinonyl conjugates and oxoquinazolin-3(4H)-yl-piperidinonyl conjugates and methods of treating medical disorders using same |
US20180078539A1 (en) | 2016-03-23 | 2018-03-22 | Louis Habash | T-cell regulation in t-cell mediated diseases by reducing pathogenic function of th17 in a human subject through treatment with a nitroxide |
US10159665B2 (en) | 2016-03-23 | 2018-12-25 | Louis Habash | Preventing amyloid plaque formation by treating a human subject with a nitroxide |
US10231959B2 (en) | 2016-03-23 | 2019-03-19 | Louis Habash | Increasing expression level of apoptosis-related genes by treating a human subject with a nitroxide |
CA3056059C (en) * | 2016-03-23 | 2023-02-14 | Louis Habash | Increasing expression level of apoptosis-related genes by treating a human subject with a nitroxide |
EP3455219A4 (en) | 2016-05-10 | 2019-12-18 | C4 Therapeutics, Inc. | AMINE-LINKED C3-GLUTARIMIDE DEGRONIMERS FOR THE DEGRADATION OF TARGET PROTEINS |
WO2017197055A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Heterocyclic degronimers for target protein degradation |
CN109562113A (zh) | 2016-05-10 | 2019-04-02 | C4医药公司 | 用于靶蛋白降解的螺环降解决定子体 |
CN109641874A (zh) | 2016-05-10 | 2019-04-16 | C4医药公司 | 用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体 |
KR20220028178A (ko) | 2016-12-16 | 2022-03-08 | 강푸 바이오파마슈티칼즈 리미티드 | 조성물, 이의 적용 및 치료 방법 |
CN110769822A (zh) | 2017-06-20 | 2020-02-07 | C4医药公司 | 用于蛋白降解的n/o-连接的降解决定子和降解决定子体 |
SG11202000143PA (en) | 2017-07-10 | 2020-02-27 | Celgene Corp | Antiproliferative compounds and methods of use thereof |
CN111315735B (zh) | 2017-09-04 | 2024-03-08 | C4医药公司 | 二氢苯并咪唑酮 |
CN111278815B (zh) | 2017-09-04 | 2024-03-08 | C4医药公司 | 戊二酰亚胺 |
CN111278816B (zh) | 2017-09-04 | 2024-03-15 | C4医药公司 | 二氢喹啉酮 |
EP3710002A4 (en) | 2017-11-16 | 2021-07-07 | C4 Therapeutics, Inc. | DEGRADER AND DEGRONE FOR TARGETED PROTEIN DEGRADATION |
WO2019191112A1 (en) | 2018-03-26 | 2019-10-03 | C4 Therapeutics, Inc. | Cereblon binders for the degradation of ikaros |
CN110357889B (zh) * | 2018-04-09 | 2022-03-15 | 上海科技大学 | 蛋白降解靶向化合物、其抗肿瘤应用、其中间体及中间体应用 |
WO2019204354A1 (en) | 2018-04-16 | 2019-10-24 | C4 Therapeutics, Inc. | Spirocyclic compounds |
WO2019209692A1 (en) | 2018-04-23 | 2019-10-31 | Celgene Corporation | Substituted 4-aminoisoindoline-1,3-dione compounds and their use for treating lymphoma |
EP3578561A1 (en) | 2018-06-04 | 2019-12-11 | F. Hoffmann-La Roche AG | Spiro compounds |
JOP20210001A1 (ar) * | 2018-07-10 | 2021-01-05 | Novartis Ag | مشتقات 3-(5- هيدروكسي -1- أوكسو أيزو إندولين -2- يل) بيبريدين -2، 6- دايون واستخدامها لمعالجة أمراض مرتبطة ببروتين ذات أصبع الزنك من عائلة (ikaros 2 (ikzf2 |
JP7168773B2 (ja) * | 2018-09-30 | 2022-11-09 | 上海 インスティテュート オブ マテリア メディカ、チャイニーズ アカデミー オブ サイエンシーズ | イソインドリン化合物、その調製方法、医薬組成物および使用 |
US11529339B2 (en) | 2018-10-01 | 2022-12-20 | Celgene Corporation | Combination therapy for the treatment of cancer |
WO2020092950A1 (en) * | 2018-11-01 | 2020-05-07 | Northwestern University | Targeting pleckstrin-2 for treating cancer |
CN111285850B (zh) | 2018-12-06 | 2022-04-22 | 中国科学院上海药物研究所 | 一类异吲哚啉类化合物、其制备方法、药物组合物及其应用 |
FI3962489T3 (fi) * | 2019-02-22 | 2023-06-09 | Elkem Silicones Usa Corp | Lääkeaineen antamiseen tarkoitettu silikonikoostumus vaikuttavan aineen eluution parantamiseksi |
CN111747924B (zh) * | 2019-03-29 | 2023-11-10 | 华东师范大学 | 一类来那度胺/泊马度胺类似物及其应用 |
BR112021019669A2 (pt) | 2019-04-12 | 2021-12-07 | C4 Therapeutics Inc | Composto, composição farmacêutica, método para tratar um transtorno, composto para uso na produção de um medicamento, e, uso de um composto no tratamento de um transtorno |
TWI762939B (zh) | 2019-05-31 | 2022-05-01 | 大陸商海思科醫藥集團股份有限公司 | Btk抑制劑環衍生物及其製備方法和藥學上的應用 |
KR20220145366A (ko) * | 2020-02-25 | 2022-10-28 | 상하이테크 유니버시티 | 글루타르이미드 골격을 기초로 하는 화합물 및 그 응용 |
AU2021255966A1 (en) * | 2020-04-17 | 2022-11-17 | Escient Pharmaceuticals, Inc. | Modulators of mas-related G-protein receptor X4 and related products and methods |
MX2023000868A (es) * | 2020-07-20 | 2023-02-22 | Jiangsu Hengrui Pharmaceuticals Co Ltd | Derivado de isoindolina que contiene azufre, metodo de preparacion y uso medico del mismo. |
TW202241872A (zh) * | 2021-01-05 | 2022-11-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 稠雜環基取代的環己二醯亞胺衍生物、其製備方法及其在醫藥上的應用 |
WO2022152821A1 (en) | 2021-01-13 | 2022-07-21 | Monte Rosa Therapeutics Ag | Isoindolinone compounds |
CN115504963A (zh) * | 2021-06-22 | 2022-12-23 | 苏州开拓药业股份有限公司 | 一种c-Myc蛋白降解剂 |
KR20240136385A (ko) | 2022-01-19 | 2024-09-13 | 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 | 황을 함유하는 이소인돌린계 유도체의 결정형 |
WO2024097932A1 (en) * | 2022-11-04 | 2024-05-10 | Bristol-Myers Squibb Company | Compounds and their use for treatment of hemoglobinopathies |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4994443A (en) | 1982-12-20 | 1991-02-19 | The Children's Medical Center Corporation | Inhibition of angiogenesis |
US5001116A (en) | 1982-12-20 | 1991-03-19 | The Children's Medical Center Corporation | Inhibition of angiogenesis |
US5800819A (en) | 1996-01-25 | 1998-09-01 | National Institute For Pharmaceutical Research And Development Federal Ministry Of Science And Technology | Piper guineense, pterocarpus osun, eugenia caryophyllata, and sorghum bicolor extracts for treating sickle cell disease |
KR19980074060A (ko) * | 1997-03-21 | 1998-11-05 | 김윤배 | 신규한 치환된 3,4-디알콕시페닐 유도체 |
TR200101500T2 (tr) * | 1998-03-16 | 2002-06-21 | Celgene Corporation | 2-(2,6-dioksopiperidin-3-il)izoindolin türevleri, bunların hazırlanması ve enflamatuarn sitokinlerin inhibitörleri olarak kullanımı. |
US6458810B1 (en) * | 2000-11-14 | 2002-10-01 | George Muller | Pharmaceutically active isoindoline derivatives |
US20030045552A1 (en) * | 2000-12-27 | 2003-03-06 | Robarge Michael J. | Isoindole-imide compounds, compositions, and uses thereof |
US7320992B2 (en) | 2003-08-25 | 2008-01-22 | Amgen Inc. | Substituted 2,3-dihydro-1h-isoindol-1-one derivatives and methods of use |
CN1867331B (zh) * | 2003-09-17 | 2010-05-26 | 美国政府健康及人类服务部 | 作为TNF-α调节剂的沙利度胺类似物 |
GB0324790D0 (en) * | 2003-10-24 | 2003-11-26 | Astrazeneca Ab | Amide derivatives |
ZA200704964B (en) | 2004-12-01 | 2008-10-29 | Celgene Corp | Methods and compositions using immunomodulatory compounds for the treatment of immunodeficiency disorders |
MX2007007424A (es) * | 2004-12-24 | 2007-07-17 | Astrazeneca Ab | Derivados de amina. |
KR20090121400A (ko) * | 2007-03-20 | 2009-11-25 | 셀진 코포레이션 | 4'-o-치환된 아이소인돌린 유도체 및 이를 포함하는 조성물 및 이의 사용 방법 |
-
2008
- 2008-03-19 KR KR1020097021797A patent/KR20090121400A/ko active Application Filing
- 2008-03-19 ES ES08726977.5T patent/ES2601131T3/es active Active
- 2008-03-19 NZ NZ599199A patent/NZ599199A/xx not_active IP Right Cessation
- 2008-03-19 US US12/077,715 patent/US8153659B2/en active Active
- 2008-03-19 EP EP08726977.5A patent/EP2142534B1/en active Active
- 2008-03-19 CN CN201310547773.7A patent/CN103641814A/zh active Pending
- 2008-03-19 JP JP2009554563A patent/JP2010522170A/ja not_active Withdrawn
- 2008-03-19 CA CA2681633A patent/CA2681633C/en active Active
- 2008-03-19 RU RU2009138500/04A patent/RU2471794C2/ru active
- 2008-03-19 MX MX2009010082A patent/MX2009010082A/es active IP Right Grant
- 2008-03-19 KR KR1020177021704A patent/KR20170093996A/ko not_active Application Discontinuation
- 2008-03-19 AR ARP080101179A patent/AR065810A1/es not_active Application Discontinuation
- 2008-03-19 EP EP16170365.7A patent/EP3101017B1/en active Active
- 2008-03-19 ES ES16170365T patent/ES2734253T3/es active Active
- 2008-03-19 AU AU2008229383A patent/AU2008229383B2/en active Active
- 2008-03-19 NZ NZ579890A patent/NZ579890A/en not_active IP Right Cessation
- 2008-03-19 CN CN200880016715A patent/CN101679380A/zh active Pending
- 2008-03-19 WO PCT/US2008/003602 patent/WO2008115516A2/en active Application Filing
- 2008-03-19 BR BRPI0809011A patent/BRPI0809011A8/pt not_active Application Discontinuation
- 2008-03-19 MY MYPI20093935A patent/MY180812A/en unknown
- 2008-03-19 UA UAA200910592A patent/UA97976C2/ru unknown
- 2008-03-19 KR KR1020157009558A patent/KR101791757B1/ko active IP Right Grant
- 2008-03-20 CL CL2008000805A patent/CL2008000805A1/es unknown
- 2008-03-24 UY UY30977A patent/UY30977A1/es not_active Application Discontinuation
- 2008-03-24 PE PE2008000525A patent/PE20081894A1/es not_active Application Discontinuation
-
2009
- 2009-09-16 IL IL200990A patent/IL200990A/en not_active IP Right Cessation
- 2009-09-17 ZA ZA2009/06497A patent/ZA200906497B/en unknown
- 2009-09-18 NI NI200900170A patent/NI200900170A/es unknown
- 2009-09-21 CR CR11036A patent/CR11036A/es unknown
- 2009-09-30 CO CO09106869A patent/CO6231033A2/es not_active Application Discontinuation
- 2009-09-30 EC EC2009009663A patent/ECSP099663A/es unknown
-
2012
- 2012-03-01 US US13/410,216 patent/US8614328B2/en not_active Ceased
-
2013
- 2013-11-18 US US14/083,205 patent/US9181216B2/en active Active
-
2014
- 2014-06-25 JP JP2014129790A patent/JP5927241B2/ja active Active
- 2014-07-16 US US14/333,454 patent/USRE46639E1/en active Active
- 2014-08-01 CR CR20140368A patent/CR20140368A/es unknown
-
2015
- 2015-10-02 US US14/874,318 patent/US9920027B2/en active Active
- 2015-10-28 JP JP2015211991A patent/JP6373818B2/ja active Active
-
2017
- 2017-08-10 JP JP2017155657A patent/JP6448726B2/ja active Active
-
2018
- 2018-02-02 US US15/887,838 patent/US10385037B2/en active Active
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2018021046A5 (ja) | ||
JP2018048154A5 (ja) | ||
RU2018133298A (ru) | Способы применения агонистов fxr | |
JP2013519675A5 (ja) | ||
JP2008528514A5 (ja) | ||
JP2017528507A5 (ja) | ||
JP2017528503A5 (ja) | ||
JP2016528301A5 (ja) | ||
JP2010504973A5 (ja) | ||
WO2014205229A8 (en) | Use of high dose pridopidine for treating huntington's disease | |
JP2009506117A5 (ja) | ||
JP2018537507A5 (ja) | ||
JP2017531619A5 (ja) | ||
JP2014198723A5 (ja) | ||
JP2020097577A5 (ja) | ||
RU2019100037A (ru) | Способ лечения рассеянного склероза с использованием ингибитора lsd1 | |
JP2017522300A5 (ja) | ||
JP2016510326A5 (ja) | ||
RU2018136580A (ru) | Цитратная соль (s)-4-((s)-3-фтор-3-(2-(5,6,7,8-тетрагидро-1,8-нафтиридин-2-ил)этил)пирролидин-1-ил)-3-(3-(2-метоксиэтокси)фенил)бутановой кислоты | |
JP2020529995A5 (ja) | ||
JP2019218379A5 (ja) | ||
JP2014148552A5 (ja) | ||
PH12017501829A1 (en) | Pharmaceutical formulations | |
JP2019507786A5 (ja) | ||
JP2020515523A5 (ja) |